INTRODUCTION: Activating mutations in the @entity470 gene ( @entity470 ) predict for prolonged progression-free survival in @entity1 with advanced @entity1149 ( @entity1149 ) treated with @entity470 @entity4149 kinase inhibitors ( @entity470 -TKIs) versus chemotherapy. Long-term survival outcomes, however, remain undefined. The objective of this study was to determine the 5-year survival in these @entity1 and identify clinical factors associated with @entity1349 ( @entity1349 ). METHODS: @entity1 with @entity470 -mutant metastatic @entity2220 who had been treated with @entity3866 or @entity4562 at Dana-Farber @entity5 Institute between 2002 and 2009 were included. @entity1349 was analyzed. RESULTS: Among 137 @entity1 , median progression-free survival and @entity1349 were 12.1 months (95% CI: 10.2-13.5) and 30.9 months (95% CI: 28.2-35.7), respectively. Twenty @entity1 (14.6%) were 5-year survivors. In multivariate analysis, exon 19 deletions (hazard ratio [HR]  = 0.63, 95% CI: 0.44-0.91, p  = 0.01), absence of extrathoracic (HR  = 0.62, 95% CI: 0.41-0.93, p  = 0.02) or brain @entity3 (HR  = 0.48, 95% CI: 0.30-0.77, p  = 0.002), and not a current smoker (HR  = 0.23, 95% CI: 0.09-0.59, p  = 0.002) were associated with prolonged @entity1349 . Age; sex; stage at diagnosis; liver, bone, or adrenal @entity3 ; specific TKI; and line of TKI therapy were not associated with @entity1349 . CONCLUSIONS: Our data suggest that the rate of 5-year survival among @entity1 with @entity470 -mutant metastatic @entity2220 treated with @entity3866 or @entity4562 is 14.6%. Exon 19 deletions and absence of extrathoracic or brain @entity3 are associated with prolonged survival. On the basis of our findings, clinicians can gain an enhanced estimation of long-term outcomes in this population.

Five-Year Survival in @entity470 -Mutant Metastatic Lung Adenocarcinoma Treated with XXXX -TKIs.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity4562 :: ('MESH:C419708', 'Chemical') :: ['gefitinib'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity3866 :: ('MESH:C400278', 'Chemical') :: ['erlotinib'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity2220 :: ('MESH:C538231', 'Disease') :: ['lung adenocarcinoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity470 :: (1956,Gene) :: ['EGFR']
